News
06-07-2010, 10:04 PM
Exelixis, Inc. today reported updated interim data from three ongoing trials of XL147 (SAR245408), a selective, orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K). Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy.
More... (http://www.news-medical.net/news/20100608/Interim-data-from-multiple-ongoing-trials-of-XL147-PI3K-inhibitor-to-be-presented-at-ASCO-2010.aspx)
More... (http://www.news-medical.net/news/20100608/Interim-data-from-multiple-ongoing-trials-of-XL147-PI3K-inhibitor-to-be-presented-at-ASCO-2010.aspx)